Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | E3311: outcomes by tobacco history in HPV+ oropharynx cancer

Ranee Mehra • 4 Jun 2022
ASCO 2022
Head and Neck Cancer
E3311

E3311 (NCT01898494) is a Phase II randomized study which showed favorable outcomes among intermediate risk HPV+ oropharynx cancer (OPC) patients who underwent transoral surgery (TOS) followed by pathology-guided or adapted, deintensified adjuvant treatment. Ranee Mehra, MD, University of Maryland Marlene & Stewart Greenebaum Cancer Center, Baltimore, MD, explores survival outcomes based on tobacco history. No differences were observed in progression-free survival (PFS) or overall-survival (OS) outcomes at three years between patients with less than or greater than 10 pack year smoking history as well as current versus former smokers. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Ranee Mehra

E3311: exploring deintensification of adjuvant treatment in patients with intermediate risk HPV+ OPC
0:59
E3311: exploring deintensification of adjuvant treatment in patients with intermediate risk HPV+ OPC
Ranee Mehra • 4 Jun 2022
KEYNOTE-012: retrospective analysis exploring potential biomarkers for IO in advanced solid tumors
0:42
KEYNOTE-012: retrospective analysis exploring potential biomarkers for IO in advanced solid tumors
Ranee Mehra • 4 Jun 2022

Related Videos

IMRT deintensification in early-stage oropharyngeal cancer: insights from the JCOG1208 trial
0:34
IMRT deintensification in early-stage oropharyngeal cancer: insights from the JCOG1208 trial
Satoaki Nakamura • 16 May 2026
Considerations for HPV status in the JCOG1208 trial of IMRT in early-stage oropharyngeal cancer
0:41
Considerations for HPV status in the JCOG1208 trial of IMRT in early-stage oropharyngeal cancer
Satoaki Nakamura • 16 May 2026
Can IMRT alone be used for higher-risk oropharyngeal cancer?
0:42
Can IMRT alone be used for higher-risk oropharyngeal cancer?
Satoaki Nakamura • 16 May 2026
Could cemiplimab replace HHI therapy in BCCHN?
0:36
Could cemiplimab replace HHI therapy in BCCHN?
Hannah Kenny • 30 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals